リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Molecular epidemiology of Enterobacter cloacae complex isolates with reduced carbapenem susceptibility recovered by blood culture」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Molecular epidemiology of Enterobacter cloacae complex isolates with reduced carbapenem susceptibility recovered by blood culture

Emiachchi Kankanamalage Sarangi Jayathilake 名古屋大学

2021.12.20

概要

【Introduction】
Although Enterobacter cloacae complex (ECC) is one of the most common causes of bacteraemia, reported to lead poor clinical outcome, only limited molecular epidemiological information on invasive reduced-carbapenem-susceptible (RCS) non-carbapenemase- producing ECC isolates is available. Therefore, we conducted a study of multicentre isolates to clarify the genetic backgrounds and antimicrobial susceptibility profiles of the RCS ECC isolates from blood samples by excluding carbapenemase producers because plasmid-mediated genes for carbapenemases can spread among bacteria with different traits, making it difficult to analyse and interpret the genetic lineages of RCS ECC isolates

【Methods】
One ECC blood isolate was collected separately from each of the 42 hospitals across Japan between 2017 and 2019. The minimum inhibitory concentrations (MICs) were measured by agar dilution antimicrobial susceptibility testing. Isolates for which imipenem MICs of ≥0.5 µg/mL were assigned the RCS group and those for which imipenem MICs of ≤0.125 µg/mL were assigned the carbapenem-susceptible (CS) group. The draft whole- genome sequence of each isolate was determined using the MiSeq platform. Expression levels of genes involved in carbapenem susceptibility was evaluated by real-time qPCR for assays of ampC, ompC, ompF transcripts. An in-house python script was used to extract ampC, ampD, ampR and ampG gene sequences from draft genome sequences. The RCS and CS groups were compared using Fisher’s exact test for categorical variables. The relative changes in gene expression were analysed using the Wilcoxon rank-sum test.

【Results】
A total of 42 ECC blood isolates representing eight geographic regions in Japan were obtained of which 21 were assigned equally by chance to each group.

The isolates were obtained from 42 patients admitted to 42 hospitals aged 53 to 97 years (median, 80 years; interquartile range, 71–88 years), of whom 45% were male and 55% were female.

All the isolates in the RCS group were resistant to cefmetazole and susceptible to amikacin, while the remaining isolates of the CS group were all susceptible to cefepime, amikacin, ciprofloxacin, and colistin. The prevalence of resistance was <25% to all the antimicrobials tested except cefmetazole and tigecycline in both groups (Table 1).

Chromosomally encoded ACT type class C β-lactamase genes were detected in all the isolates in the CS group, and 16/21 isolates (76%) in the RCS group (Table 2). Two isolates of the RCS group harboured both class C (ACT) and class A (CTX-M or TEM) β-lactamase genes. The most common subtype of the ACT gene was ACT-7, which was present in 6/21 (28%) of the RCS group and 7/21 (33%) of the CS group.

The RCS group isolates belonged to six species ( E. hormaechei, E. kobei, E. ludwigii, E. roggenkampii, E. asburiae, and E. bugandensis) and the CS group isolates belonged to three species (E. hormaechei, E. kobei, and E. ludwigii). Only the E. roggenkampii isolates belonging to the RCS group harboured genes for MIR (n=2) or CMG (n=3) type class C β- lactamases.

Multilocus sequence type (MLST) analysis distinguished 36 STs among the 42 isolates, indicating high genetic diversity (Fig. 1, Table 3, Table 4). Among these 36 STs, 8 STs(1196, 1197, 1252, 1253, 1255, 1256, 1258, 1259) were newly identified in the RCS group and three new STs (1204, 1254, 1257) were identified in the CS group.

Analysis of ampD and ampR revealed an Ile259Val substitution in AmpR and Pro28His, Ile48Asp, Trp95Arg, His19Tyr, and Asp164Ala substitutions in AmpD were exclusive to the E. hormaechei ssp. steigerwaltii RCS isolates while sample 5 had truncated AmpD caused by premature stop codon at position 95 (Fig. 2).

The differences in the relative ampC, ompC, and ompF genes expressions between the RCS and CS groups were statistically significant (p<0.001), (p=0.005) and (p=0.003) respectively. An RCS group member strain 24017 was excluded from statistical analysis of the ampC, ompC, ompF transcripts as no evident relative increase in the expression of the ampC gene was detected, and failed to identify Class A and/or D β-lactamases in this strain. Therefore, factors contributing to RCS phenotype of strain 24017 should be further explored. Reduction in the expression of either major porin channel was not detected in the RCS group member strain 23635 (sample 1), but both ACT and CTX-M-9 type β-lactamases were identified. Increased expression of the ampC gene and decreased expression of the ompF gene were exclusively identified in all the other members of the RCS group (Fig. 2).

【Discussion】
Enterobacter spp. have emerged as one of the main causes of bacteraemia following Escherichia coli and Klebsiella pneumoniae. K. pneumoniae ST14 and ST258 and Pseudomonas aeruginosa ST235 were identified as specific genetic lineages that cause invasive infections with carbapenem-resistant bacteria. However, there is limited information on the specific genetic lineages of ECC that cause invasive infections.

Genetic diversity of ECC blood isolates has been demonstrated by Wang et al. in China with 51 STs from 53 isolates. The authors did not specify the carbapenem resistance and carbapenemase production of each isolate, but the majority of the CS isolates were non- carbapenemase-producers. Tetsuka et al. demonstrated genetic divergence among three carbapenem-resistant ECC blood isolates producing no carbapenemases.

We found that the RCS non-carbapenemase-producing ECC blood isolates belonged to distinct species, sequence types and produced distinct types of class C β-lactamases. This suggests that the selection of RCS mutant among ECC blood isolates is independent of species, sequence types and type of class C β-lactamases produced. Therefore, RCS phenotype might independently evolve from CS phenotypes of ECC representing diverse genetic backgrounds.

ECC Hoffmann cluster IV was defined as a novel species of E. roggenkampii by Sutton et al. in 2018. Non-carbapenemase-producing carbapenem-resistant ECC Hoffmann cluster IV blood isolates have been reported in Nagoya University hospital. An RCS ECC Hoffmann cluster IV blood isolate belonged to ST997 carrying both IncFIB and IncN plasmids that mediated genes for IMP-1 metallo-β-lactamase, CTX-M-14 extended- spectrum β lactamase, and MIR-6 type class C β-lactamase was reported in Japan. E. roggenkampii was recently established as a novel species. Thus, knowledge of its carbapenem susceptibility is limited. We found that the five E. roggenkampii blood isolates with the RCS phenotype had different sequence types, suggesting polyclonal spread.

The association between single nucleotide polymorphisms in the ampD gene with derepression of ampC leading to cephalosporin resistance has been shown. Our study showed an association of AmpC increased production and OmpF decreased production with reduced-carbapenem susceptibility in E. hormaechei ssp. steigerwaltii. Thus, replacement of larger channel OmpF with smaller channel OmpC in E. hormaechei ssp. steigerwaltii might contribute to decreased efficacy of carbapenems by maintaining their concentration in the periplasm below saturation level by facilitating activity of low level carbapenem hydrolysing β-lactamases.

Indeed, MIC ≥4 µg/mL is the criterion for resistance to diagnose clinical resistance in imipenem and meropenem, but a cut-off value of imipenem MIC ≥0.5 µg/mL was used to define the RCS group for comparative characterization of bacterial isolates for which carbapenem MICs are just below the breakpoint for “resistance” to exactly perform present study.

【Conclusion】
The results observed in this study suggested that almost all ECC isolates have the potential to develop the RCS phenotype regardless of their genotype and species. Which emphasizes the necessity of prudent antibacterial treatments and infection control measures against ECC blood isolates irrespective of their genomic STs or β-lactamase types.

この論文で使われている画像

参考文献

1, Lee Y, Choi H, Yum JH, et al. Molecular mechanisms of carbapenem resistance in Enterobacter cloacae clinical isolates from Korea and clinical outcome. Ann Clin Lab Sci. 2012;42:281-6.

2. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol. 2011;65:455-78.

3. National Institute of Infectious Diseases. Carbapenem-resistant Enterobacteriaceae (CRE) Infection, Japan. Infect Agents Surveillance Rep. 2019;40:17-8.

4. National Institute of Infectious Diseases. Carbapenem-resistant Enterobacteriaceae Infection, Japan. Infect Agents Surveillance Rep. 2014;35:281-2.

5. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev. 2009;22:161-82.

6. Tamma PD, Doi Y, Bonomo RA, et al. Antibacterial Resistance Leadership Group. 2019. A primer on AmpC β-lactamases: Necessary knowledge for an increasingly multidrug-resistant world. Clin Infect Dis. 2019;69:1446-55.

7. Szabó D, Silveira F, Hujer AM, et al. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother. 2006; 50:2833-5.

8. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-90.

9. Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother. 2017;61:e02349-16.

10. Yaita K, Gotoh K, Nakano R, et al. Biofilm-forming by carbapenem-resistant Enterobacteriaceae may contribute to the blood stream infection. Int J Mol Sci. 2019;20:5954.

11. Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28:565-591.

12. Chavda KD, Chen L, Fouts DE, et al. Comprehensive genome analysis of carbapenemase-producing Enterobacter spp.: New insights into phylogeny, population structure, and resistance mechanisms. mBio. 2016;7:e02093-16.

13. Aoki K, Harada S, Yahara K, et al. Molecular characterization of IMP-1- producing Enterobacter cloacae complex Isolates in Tokyo. Antimicrob Agents Chemother. 2018;62:e02091-17.

14. Hishinuma T, Tada T, Kuwahara-Arai K, et al. Spread of GES-5 carbapenemase-producing Pseudomonas aeruginosa clinical isolates in Japan due to clonal expansion of ST235. PLoS One. 2018;13:e0207134.

15. Perilli M, Sabatini A, Pontieri E, et al. OXA-23 carbapenemase in multidrug- resistant Acinetobacter baumannii ST2 Type: First identification in L'Aquila Hospital (Italy). Microb Drug Resist. 2015;21:97-101.

16. Tetsuka N, Hirabayashi A, Matsumoto A, et al. Molecular epidemiological analysis and risk factors for acquisition of carbapenemase-producing Enterobacter cloacae complex in a Japanese university hospital. Antimicrob Resist Infect Control. 2019;8:126.

17. Bush K, Bradford PA. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev. 2020;33:e00047-19.

18. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed, M7-A10. Clinical and Laboratory Standards Institute, Wayne, PA; 2015.

19. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0; 2019.

20. Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing, 27th ed, M100. Clinical and Laboratory Standards Institute, Wayne, PA; 2017.

21. van der Zwaluw K, de Haan A, Pluister GN, et al. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PLoS One. 2015;10:e0123690.

22. Coil D, Jospin G, Darling AE. A5-miseq: An updated pipeline to assemble microbial genomes from Illumina MiSeq data. Bioinformatics. 2014;31:587-9.

23. Richter M, Rosselló-Móra R. Shifting the genomic gold standard for the prokaryotic species definition. Proc Natl Acad Sci U S A. 2009;106:19126-31.

24. Majewski P, Wieczorek P, Ojdana D, et al. Altered outer membrane transcriptome balance with AmpC overexpression in carbapenem-resistant Enterobacter cloacae. Front Microbiol. 2016;7:2054.

25. Cai Y, Chen C, Zhao M, et al. High prevalence of metallo-β-lactamase- producing Enterobacter cloacae from three tertiary hospitals in China. Front Microbiol. 2019;10:1610.

26. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452-8.

27. Mack AR, Barnes MD, Taracila MA, et al. A standard numbering scheme for class C β-lactamases. Antimicrob Agents Chemother. 2020;64:e01841-19.

28. Kallel H, Houcke S, Resiere D, et al. Epidemiology and prognosis of intensive care unit-acquired bloodstream infection. Am J Trop Med Hyg. 2020;103:508- 14.

29. Piccirilli A, Perilli M, Piccirilli V, et al. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae ST14 and ST512 causing bloodstream infections in ICU and surgery wards of a tertiary university hospital of Verona (northern Italy): Co-production of KPC-3, OXA-48, and CTX-M-15 β-lactamases. Diagn Microbiol Infect Dis. 2020;96:114968.

30. Kontopoulou K, Iosifidis E, Antoniadou E, et al. The clinical significance of carbapenem-resistant Klebsiella pneumoniae rectal colonization in critically ill patients: From colonization to bloodstream infection. J Med Microbiol. 2019;68:326-35.

31. Wang S, Xiao SZ, Gu FF, et al. Antimicrobial susceptibility and molecular epidemiology of clinical Enterobacter cloacae bloodstream isolates in Shanghai, China. PLoS One. 2017;12:e0189713.

32. Mori N, Kagawa N, Aoki K, et al. Clinical and molecular analyses of bloodstream infections caused by IMP metallo-β-lactamase-producing Enterobacteriaceae in a tertiary hospital in Japan. J Infect Chemother. 2020;26:144-7.

33. Kananizadeh P, Oshiro S, Watanabe S, et al. Emergence of carbapenem- resistant and colistin-susceptible Enterobacter cloacae complex co-harboring bla(IMP-1) and mcr-9 in Japan. BMC Infect Dis. 2020;20:282.

34. Sutton GG, Brinkac LM, Clarke TH, et al. Enterobacter hormaechei subsp. hoffmannii subsp. nov., Enterobacter hormaechei subsp. xiangfangensis comb. nov., Enterobacter roggenkampii sp. nov., and Enterobacter muelleri is a later heterotypic synonym of Enterobacter asburiae based on computational analysis of sequenced Enterobacter genomes. F1000Res. 2018;7:521.

35. Zhou K, Yu W, Cao X, Shen P, et al. Characterization of the population structure, drug resistance mechanisms and plasmids of the community- associated Enterobacter cloacae complex in China. J Antimicrob Chemother. 2017;73:66-76.

36. Babouee Flury B, Ellington MJ, Hopkins KL, et al. Association of novel nonsynonymous single nucleotide polymorphisms in ampD with cephalosporin resistance and phylogenetic variations in ampC, ampR, ompF, and ompC in Enterobacter cloacae isolates that are highly resistant to carbapenems. Antimicrob Agents Chemother. 2016;60:2383-90.

37. Majewski P, Gutowska A, Sacha P, et al. Expression of AraC/XylS stress response regulators in two distinct carbapenem-resistant Enterobacter cloacae ST89 biotypes. J Antimicrob Chemother. 2020;75:1146-50.

38. Galdiero S, Falanga A, Cantisani M, et al. Microbe-host interactions: structure and role of Gram-negative bacterial porins. Curr Protein Pept Sci. 2012;13:843-54.

参考文献をもっと見る